Shockwave Medical
Shockwave Medical, part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Its Reducer technology, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom, is designed to provide relief to the millions of patients worldwide suffering from refractory angina by redistributing blood flow within the heart. Learn more at www.shockwavemedical.com.
DISRUPT BTK II Acute Outcomes: Physician Perspectives
Join Dr. Nick West, Chief Medical Officer of Shockwave Medical, Dr. Raghuram Lakshminarayan, Hull Royal Infirmary, UK, and Professor Andrew Holder, Auckland City Hospital, New Zealand, as they discuss the DISRUPT BTK II acute outcomes data at CIRSE 2024 in under ten minutes The physicians appearing in this video are paid consultants of Shockwave Medical. The thoughts and views expressed are of their own opinions, and do not necessarily reflect Shockwave Medical.
Shockwave Important Safety Information: https://shockwavemedical.com/important-safety-information-universal/
